AI is moving into care, billing, and security faster than many health systems can review it. My read on this article is simple: if you lead IT, security, clinical informatics, compliance, or sit on a board, this webinar series matters because it turns scattered AI concerns into a set review process.
Here’s the short version:
- Clinical AI can affect patient safety and care gaps.
- Admin AI can spread billing mistakes, delay authorizations, and create compliance trouble.
- Security AI can miss threats or flood teams with false alerts.
- Standard software reviews are not enough for AI because AI also needs checks for bias, explainability, drift, data fit, and model changes.
- Vendor review has to go deeper into PHI use, subprocessors, cloud links, logs, incident response, and model transparency.
- Leadership needs one shared process instead of separate reviews by IT, clinical, security, and compliance teams.
A few facts stand out. The article points to research showing that clinical decision support AI trained on nonrepresentative data can increase racial and ethnic disparities. It also notes that AI now shows up across EHR documentation, revenue cycle, imaging, scheduling, and security tools. So this is not a future problem. It is a current review and risk problem.
What I find most useful is that the series is not just about AI theory. It gives leaders a way to work through:
- governance and accountability
- third-party AI supply chain review
- cyber abuse cases like prompt injection and API misuse
- resilience and continuity planning
- safe clinical workflow use
- intake and procurement rules for AI tools
Bottom line: I’d pay attention to this series if my health system lacks a clear AI review path, if vendors are adding AI into products I already use, or if my board wants proof that AI decisions are being tracked and documented.
This article, at its core, says one thing: health systems need one repeatable way to review AI before AI use spreads further inside the enterprise.
Healthcare AI Governance - Risks, Compliance, and Frameworks Explained
sbb-itb-535baee
The AI risk problem inside health systems
AI now sits inside EHR documentation tools, revenue cycle platforms, imaging systems, scheduling software, and security operations centers. Once it becomes part of day-to-day work, a failure doesn't stay in one lane. It can hit care, billing, compliance, and security at the same time.
The webinar series gives leaders a clear way to assess that risk before adoption spreads any further. That's why health systems need one shared way to evaluate AI before deployment.
How clinical, administrative, and cyber AI use cases create different risks
Each type of AI deployment brings a different kind of risk. So the controls can't be one-size-fits-all.
Clinical AI - such as imaging support, triage, and clinical decision support - carries the highest patient safety risk. Research from AHRQ and other researchers found that clinical decision support AI trained on nonrepresentative data can widen racial and ethnic disparities [2]. That means the tool needs clinical review, not just IT sign-off.
Administrative AI has an indirect effect on care, but it can still create serious operating risk. An AI coding engine that spreads billing errors can lead to compliance exposure and lost revenue. An AI-assisted prior authorization tool that reads documentation the wrong way can delay a patient's access to care. The downstream effect on operations and access is serious enough to deserve the same scrutiny given to clinical tools. In other words, governance can't stop at the bedside.
Cybersecurity AI comes with a different risk profile. AI-assisted threat detection can speed up detection, but if the model is trained on incomplete data or tuned poorly, it may produce false negatives that miss actual incidents - or false positives that bury already stretched security teams in noise. Attackers can also use prompt injection or API abuse to weaken detection. So security AI needs its own validation standard, separate from general IT controls.
Why standard review processes fall short for AI
Standard IT and vendor risk management processes were built for static software. They usually ask a familiar set of questions: Is the product secure? Does it meet compliance rules? Will it integrate with current systems?
AI needs more than that.
It also needs review for data fit, bias, explainability, and performance drift. As one recent narrative review of AI in healthcare noted, bias, opacity, privacy, and safety risks remain persistent concerns even as AI performance improves [1]. These are not side issues to clean up later. They are part of how AI systems work from the start.
Many health systems still don't have a shared intake process, a cross-functional review team, or a post-launch monitoring standard for AI tools. A one-time approval isn't enough. AI tools need continuous monitoring and periodic revalidation as live data changes. That's the gap the webinar series helps leaders close.
The next section shows how the series turns these risks into practical leadership decisions.
How the webinar series helps leaders make better AI decisions
The series gives leaders a practical way to assess AI across clinical, administrative, and security use cases. Instead of treating every AI decision the same, it gives teams a way to use the right review lens for the job.
That matters for one simple reason: not every AI tool should go through the same type of review. A clinical workflow tool needs one kind of scrutiny. A vendor-driven admin tool needs another. A security-facing system may need a much deeper look at abuse and failure paths.
What leaders gain across clinical, administrative, and cybersecurity domains
The series pairs each AI domain with the review tool that fits it best. For executives, the value is clear. They can see what to approve, what to examine more closely, and what to keep watching after launch.
| Domain | Key Framework/Tool | Primary Focus |
|---|---|---|
| Governance | ANSI/HSI 2800:2025 | Executive accountability and lifecycle management |
| Third-Party Risk | HSCC Supply Chain Transparency Guide | Evaluating AI vendor subcontractors and model dependencies |
| Cybersecurity | AI attack-path and abuse-case guidance | Spotting model probing and agent abuse |
| Resilience | HSCC SMART Framework | Mapping systemic risks and clinical continuity planning |
| Clinical | Human-AI Partnership Model | Safe clinical workflow integration |
| Administrative | AI Procurement Policy Architecture | Standardizing how AI tools enter the organization |
For clinical leaders, the series focuses on safe clinical workflow integration. For administrative leaders, it introduces an AI procurement policy architecture that standardizes how AI tools enter the organization. For cybersecurity leaders, it addresses model probing and agent abuse.
It also shows how rural and community systems can manage AI risk with limited resources [3].
How the sessions translate technical risks into decisions leaders can make
One of the main takeaways is the HSCC SMART Framework. It helps organizations map systemic risks and build unified business and clinical continuity plans that account for AI-specific failure modes [3].
On the vendor side, the HSCC Supply Chain Transparency Guide helps leaders ask better questions about subcontractors and open-source dependencies. As Samantha Jacques, PhD, FACHE, Vice President of Clinical Engineering at McLaren Health Care, put it:
"traditional third-party risk management was never designed for AI supply chains, including the subcontractors, open-source dependencies, and models being retrained without notification." [3]
Erik Decker, Vice President and Chief Information Security Officer at Intermountain Health, reinforced why this work matters now:
"Healthcare systems that practice resiliency will be able to keep pace with these changes." [3]
Taken together, these frameworks give leaders a working base for governance, procurement, supply chain review, and resilience planning. They also help turn one-off reviews into a process teams can repeat.
Building a repeatable process for AI governance and vendor review
AI Governance in Health Systems: Manual vs. Centralized Vendor Review
Review frameworks don't do much on their own. They start to matter when they become part of how your team works every day.
The next move is to turn those frameworks into a repeatable AI governance and vendor review process. In plain terms, that means shifting from one-off reviews to a structured program with clear roles and set evaluation criteria.
A practical AI governance model for health systems
The base of this model is an AI governance committee that owns enterprise AI strategy, risk, and oversight. The CISO, compliance, legal, clinical, and operations leaders each handle their part of the review.
What makes this hold up under scrutiny? Documentation. Teams need to document intake, triage, review, approval, and escalation at each step. That structure gives health systems a clear path for vendor review, approval, and ongoing monitoring.
What to evaluate when reviewing third-party AI vendors and embedded AI tools
Once governance is in place, the next step is a steady vendor review standard. If an AI tool touches PHI or patient-facing workflows, the review needs to go deeper across a few specific areas:
- PHI handling
- Model transparency and explainability
- Clinical safety evidence
- Security controls
- Subprocessors and cloud dependencies
- Incident response
- Auditable logs
| Dimension | Manual Reviews | Centralized Workflow |
|---|---|---|
| Speed | Weeks to months; questionnaires sent by email and chased manually | Days; automated routing and AI-assisted completion |
| Consistency | Varies by reviewer; depth and focus are person-dependent | Standardized question sets, scoring models, and approval criteria applied uniformly |
| Evidence review | Documents scattered across email attachments and shared drives | AI ingests and summarizes evidence, maps it to control requirements, and flags gaps |
| Reporting and auditability | Ad hoc; difficult to produce consolidated records for regulators or auditors | Real-time dashboards, structured audit trails, and board-ready reporting |
How Censinet puts webinar guidance into practice
A centralized workflow makes that standard repeatable across the enterprise. Censinet RiskOps™ brings AI vendor assessments, enterprise risk reviews, policies, and decisions into one place. Standalone tools and embedded EHR features can be cataloged, tracked, and reassessed in the same workflow.
Censinet AI™ speeds up the parts of the process that usually eat the most time. It helps vendors complete security questionnaires faster by drawing on prior responses and existing documentation. For internal reviewers, it summarizes evidence, maps findings to specific control requirements, and flags gaps. That way, reviewers can spend more time on judgment and less time digging through documents.
Censinet AI handles routing, evidence flagging, and mitigation suggestions, while risk owners and governance committee members keep final approval for every material decision.
Conclusion: Why acting now strengthens resilience, compliance, and patient safety
AI is moving into health systems fast. Governance often isn’t. And that gap is where problems start - especially around patient safety, compliance, resilience, and data security.
For leaders who want to move from awareness to action, this series offers a shared starting point for governance. It gives teams a common basis for AI governance, including ANSI/HSI 2800:2025 and the HSCC Third-Party AI Risk and Supply Chain Transparency Guide. Together, these resources help teams make defensible decisions about risk, accountability, and vendor dependencies. They also help when boards, auditors, or regulators ask for proof.
Key takeaways for health system decision-makers
AI risk is already an enterprise issue. Every clinical, administrative, and cybersecurity AI use case creates a decision point, and each of those decisions needs structure behind it.
The practical takeaway is straightforward: governance must involve multiple teams, vendor review has to go beyond standard security questionnaires to cover subcontractors, open-source dependencies, and model updates made without notice, and board oversight has to keep pace with AI deployment while tracking new disclosure rules.
Health systems that put these controls in place now are more likely to adopt AI with fewer failures and stronger protection for patients, data, and operations.
FAQs
How should a health system start an AI review process?
Start with a cross-functional governance committee that has clear authority to make decisions. Bring in leaders from clinical, IT, security, legal, compliance, and procurement so the right people are at the table from day one.
Next, build a centralized AI inventory. Track each tool’s owner, the data types it uses, and its impact on patients. From there, sort tools into risk tiers so teams know which ones need the most review.
For clinical tools, require documented human review before AI affects care. Also add AI-specific contract terms that cover data use, rollback rights, and performance transparency.
Who should be involved in AI governance decisions?
AI governance should be led by a multidisciplinary committee with decision-making authority. It can’t sit on the sidelines as a group that only gives advice.
That committee should include clinical leadership, IT, the CISO, the Chief Privacy Officer, legal, compliance, procurement, data science, and operations. You want the people who understand patient care, risk, systems, contracts, data, and day-to-day execution all at the same table.
A senior executive should oversee this work, ideally one who reports to the CEO. That setup helps keep accountability at the board level and gives the governance group the backing it needs when hard calls have to be made.
What should we ask AI vendors before approval?
Before approving an AI vendor, make sure you can verify data safety, transparency, and accountability.
Ask direct questions:
- Are external models trained on protected health information?
- Who are the subprocessors?
- What audit artifacts can the vendor share?
You should also require a CHAI Applied Model Card that covers training data provenance, subgroup performance, and known failure modes.
On top of that, confirm that the vendor will report material algorithm changes. And make it clear that patient data cannot be used for model training.
